

1 SarZ promotes the expression of virulence factors and represses biofilm formation by modulating
2 SarA and *agr* in *Staphylococcus aureus*

3

4 Sandeep Tamber and Ambrose L. Cheung*

5

6 Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, NH 03755
7 USA

8

9 *Corresponding author:

10 Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, NH
11 03755 USA

12 Tel. (603) 650 1314

13 Fax. (603) 650 1318

14 Email. ambrose.cheung@dartmouth.edu

15

16 Running Title: Regulation of virulence and biofilm formation by SarZ

17 Key words: *Staphylococcus aureus*, virulence, biofilm formation, protease production, gene
18 regulation, SarZ, SarA, MgrA, *agr*

1 **ABSTRACT**

2 *Staphylococcus aureus* is a remarkably adaptable organism capable of multiple modes of
3 growth in the human host; as a part of the normal flora, as a pathogen, or as a biofilm. Many of
4 the regulatory pathways governing these modes of growth are centered on the activities of two
5 regulatory molecules, the DNA binding protein SarA and the regulatory RNA III effector
6 molecule of the *agr* system. Here, we describe the modulation of these regulators and their
7 downstream target genes by SarZ, a member of the SarA/MarR family of transcriptional
8 regulators. Transcriptional and phenotypic analyses of a *sarZ* mutant demonstrated that the
9 decreased transcription of *mgrA* and the *agr* RNAIII molecule was accompanied by increased
10 transcription of *spa* (protein A), and down-regulation of *hla* (alpha-hemolysin) and *sspA* (V8
11 protease) transcripts when compared to its isogenic parent. The decrease in protease activity was
12 also associated with an increase in SarA expression. Consistent with an increase in SarA levels,
13 the *sarZ* mutant displayed an enhanced ability to form biofilms. Together, our results indicate
14 that SarZ may be an important regulator governing the dissemination phase of *S. aureus*
15 infections, as it promotes toxin expression while repressing factors required for biofilm
16 formation.

17

18

19

20

1

2 INTRODUCTION

3 *Staphylococcus aureus* is a Gram-positive organism that colonizes the anterior nares of
4 approximately 30% of the normal population. Infections can occur when there is a breach in the
5 immune defenses of the host. Diseases caused by *S. aureus* vary, depending on the site of
6 colonization and can range from superficial skin lesions to invasive syndromes such as
7 pneumonia, endocarditis, osteomyelitis, and septicemia (3, 8). Adding to the seriousness of these
8 infections is the propensity of *S. aureus* to form biofilms, which often leads to the establishment
9 of chronic infections that are difficult to treat (12). The switching from the commensal, to the
10 invasive, to the biofilm modes of growth is due in part to the complex repertoire of regulatory
11 molecules that *S. aureus* uses to sense and respond to its environment.

12 The complex nature of the regulatory pathways governing virulence and biofilm
13 formation in *S. aureus* arises from the fact that multiple regulators can activate or repress a single
14 target gene. Detailed examination of the regulation of several virulence genes such as *spa*
15 (protein A), *hla* (alpha-hemolysin), and *sspA* (V8 protease) has revealed the following trends (3,
16 26-28, 36). First, gene expression occurs in a temporal fashion such that cell wall proteins and
17 surface adhesins are expressed during the early, colonizing stages of infection whereas toxins
18 and secreted proteins are expressed later, during the tissue damaging phase of disease. Second,
19 the *agr* quorum sensing system and the SarA family of DNA binding proteins form the
20 cornerstone of virulence gene regulation in staphylococci. Together, these regulators control the
21 expression of over a hundred genes that are involved in a myriad of cellular functions (11).

1 The *agr* system is comprised of two divergent transcripts (RNAII and RNAIII) that are
2 activated in response to cell density. RNAII encodes a quorum-sensing two-component
3 regulatory system (TCRS) that is activated by the autoinducing peptide, AIP. The RNAIII
4 transcript, presumably activated by its cognate TCRS, is the *agr* effector molecule that activates
5 the transcription of toxin genes such as *hla* and *sspA* and represses surface protein genes, such as
6 *spa* through its direct action or via intermediary regulators such as SarS, SarT, Rot and SaeRS
7 (14, 23, 25, 32).

8 The *sarA* gene encodes a DNA binding protein belonging to the SarA protein family of
9 winged-helix transcriptional regulators (7). The SarA protein binds and activates the promoters
10 of a number of genes including *agr* and represses other genes such as *sspA* and *spa* (5, 9). Like
11 *agr*, SarA also controls gene expression indirectly through its effect on other regulatory
12 molecules. For example, the positive effect of SarA on *hla* is believed to be mediated in part by
13 the repressor SarT (27).

14 Many members of the SarA family have been characterized and the majority of them
15 have roles in controlling the expression of genes involved in virulence (7). One SarA
16 homologue, SarZ, was previously reported to restore hemolysis in a mutant lacking that
17 capability (18). We have now expanded that role to the general promotion of virulence through
18 the activation of *agr* and repression of SarA. Additionally, we demonstrate a role for SarZ in the
19 repression of biofilm formation, presumably through its effect on *sarA*. Together, these results
20 suggest that SarZ plays an important role in the maintenance of active *S. aureus* infections.

21 MATERIALS AND METHODS

1 **Bacterial strains, growth conditions, and reagents**

2 The bacterial strains used in this study are listed in Table 1. *S. aureus* strains were
3 routinely cultured on Tryptic Soy agar/broth or 03GL broth (24). *E. coli* strains were grown on
4 Luria Bertani agar/broth. Antibiotics for plasmid selection and maintenance were used at the
5 following concentrations; *S. aureus*- 2.5 µg/mL erythromycin, 10 µg/mL chloramphenicol, *E.*
6 *coli*- 10 µg/mL ampicillin. All strains were grown in 18 mm borosilicate glass tubes at 37°C in
7 an Excella E24 incubator (New Brunswick Scientific, Edison, NJ) shaking at 250 RPM unless
8 indicated otherwise. Bacterial growth was monitored by measuring the optical density (OD) at
9 650nm on a Spectronic 20D+ spectrophotometer (Spectronic Analytical Instruments, Garforth,
10 England). Early exponential, late-exponential, and post-exponential growth phases corresponded
11 to OD readings of 0.7, 1.1, and 1.7, respectively at 650 nm.

12 All chemicals and reagents were obtained from either Fisher or Sigma unless noted
13 otherwise. Enzymes and reagents used for genetic manipulations were obtained from New
14 England Biolabs.

15 **Oligonucleotides and strain construction**

16 A list of the oligonucleotides used in this study is available from the authors upon
17 request. DNA isolation, electrophoresis, polymerase chain reactions (PCR), transformation of *E.*
18 *coli* and *S. aureus*, and other genetic manipulations were carried out according to standard
19 laboratory protocols. Plasmid DNA from *E. coli* was first introduced into the heavily
20 mutagenized, DNA restriction system deficient *S. aureus* strain RN4220 prior to transfer into
21 other *S. aureus* strains.

1 An unmarked, in-frame deletion of *sarZ* was constructed by employing a PCR SOEing
2 approach. Briefly, 1 kb regions up and downstream of the *sarZ* coding region were amplified
3 using primers with complementary 9 base pair overhangs. The resulting amplicons were used as
4 the template to create a composite DNA fragment missing *sarZ*. This fragment was cloned into
5 pMAD- a shuttle vector with a temperature sensitive origin of replication in *S. aureus* (1).
6 Through a series of temperature shifts from 30°C to 44°C, the *sarZ* deletion construct was
7 obtained via a double cross-over event in the chromosome, replacing the native *sarZ*
8 chromosomal region with the one containing the in-frame markerless deletion. A similar
9 approach, wherein the native *sarZ* gene was crossed back into the chromosome of the *sarZ*
10 mutant, was used to create the *sarZ* complemented strain. The *sarA sarZ* double mutant was
11 constructed by introducing the pMAD derivative pALC5448 into the *sarZ* mutant allowing for
12 the replacement of the native *sarA* gene with the mutant allele. Correct clones were identified by
13 PCR and confirmed by sequencing.

14 The SspA, and MgrA over-producing strains were created by amplifying the respective
15 open reading frames and cloning them downstream of the xylose inducible promoter of the *S.*
16 *aureus* expression vector pEPSA5 (13). The respective promoter sequences of these genes were
17 also amplified and cloned upstream of the *gfp_{uvr}* gene in the *E. coli-S. aureus* shuttle vector
18 pALC1484 to create transcriptional fusions (17). The RNAIII overproducing strain was
19 constructed by introducing pRN6735 into the *sarZ* mutant.

20 Northern hybridizations

1 RNA was isolated from approximately 1.6×10^{11} CFU from early exponential (OD₆₅₀ =
2 0.7), late exponential (OD₆₅₀ = 1.1), or post-exponential (OD₆₅₀ = 1.7) phase cells grown in
3 TSB. Cells were lysed in Trizol according to the manufacturer's protocol (Invitrogen, Irving,
4 CA) using 0.1 mm silica-zirconia beads and a reciprocating shaker (BIO 101, Vista, CA). Ten
5 micrograms of RNA was separated on a 1.5% agarose-0.66M formaldehyde gel in 20 mM
6 morpholinepropanesulfonic acid, 10 mM sodium acetate, 2 mM EDTA (pH 7) at 80 V for 3
7 hours, transferred to a nylon membrane (Amersham HyBond XL, GE Healthcare, Piscataway,
8 NJ) in 20X SSC (3M NaCl, 0.3 M sodium citrate, pH 7) and fixed by baking the membranes at
9 80°C for 2 hours. Membranes were prehybridized in 5X SSC, 0.5% sodium dodecyl sulfate, and
10 5X Denhardt's solution (0.1% bovine serum albumin, 0.1% Ficoll-400, 0.1%
11 polyvinylpyrrolidone) for 4 hours at 65°C. Purified DNA fragments were labeled with the
12 random primed DNA labeling kit (Hoffmann-La Roche Inc, Nutley, NJ) and allowed to
13 hybridize to the membranes overnight at 65°C. Post-hybridization, the membranes were washed
14 extensively and the bands were visualized by autoradiography. The relative intensities of the
15 resulting bands were determined by using ImageJ (30). Data shown are representative of at least
16 three hybridizations.

17 **GFP-promoter fusion analysis**

18 Shuttle plasmids containing the promoter regions of various genes driving the expression
19 of GFP_{uvr} (Table 1) were electroporated into the wild-type, *sarZ* mutant, and complemented
20 strains by electroporation as previously described (31). Overnight cultures of the resulting
21 strains were diluted 1:100 into fresh TSB, incubated at 37°C with shaking. Aliquots of the

1 cultures were removed at specified time points and their growth and fluorescence were
2 monitored using an FL600 microplate fluorescence reader (BioTek Instruments, Winooski, VT).
3 Experiments were repeated three times using four independently isolated clones read in
4 triplicate. Error bars represent standard deviations of the mean. Statistical significance was
5 calculated using the Student's t-test.

6 **SDS-PAGE and Western transfer**

7 Cell lysates were prepared by harvesting approximately 1.6×10^{11} CFU from exponential
8 phase cells, resuspending the pellets in TEG buffer (25 mM Tris-Cl, pH 8, 25 mM EGTA), and
9 lysing the cells using 0.1 mm silica-zirconia beads and a reciprocating shaker. The proteins were
10 separated from cellular debris by centrifugation at $12\ 000 \times g$ for 5 minutes at 4°C and
11 quantitated using the BCA Protein Assay kit (Pierce, Rockford, IL). An equivalent amount of
12 protein (75 μg) was separated by electrophoresis on 12.5% acrylamide gels, transferred onto
13 PVDF membranes (Polyvinylidene fluoride, Millipore, Billerica, MA) and analyzed by Western
14 blotting according to standard protocols. The primary antibody used was murine anti-SarA
15 monoclonal antibody (1:1000 dilution, 21) and the secondary antibody was donkey anti-mouse
16 IgG conjugated to horseradish peroxidase (1:10 000 dilution, Jackson ImmunoResearch
17 Laboratories, West Grove, PA). Binding of the antibodies to the membrane was detected using
18 the ECL Western blotting Detection System according to the manufacturer's instructions (GE
19 Healthcare). Densitometry was performed using ImageJ (30).

20 **Protease detection assays**

1 Protease production was tested by spotting 2 μL of 10^{10} cells/mL onto agar plates
2 containing 5% skimmed milk followed by incubation at 37°C for 24 hours. Alternatively,
3 proteins from 30 μL of culture supernatant from overnight bacterial cultures normalized to 10^{10}
4 cells/mL were separated electrophoretically on 12.5% acrylamide gels containing 1 mg/mL
5 gelatin. After electrophoresis, the gel was washed with gentle shaking in phosphate buffered
6 saline containing 2.5% Triton X-100 for one hour at room temperature and incubated overnight
7 in protease detection buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 5 mM CaCl_2 , 1 mM
8 cysteine, 0.2% Triton X-100) at 37°C with shaking. The gel was then stained in Coomassie
9 Brilliant Blue R-250 and destained according to standard procedures to visualize protease
10 activity as zones of clearing on a blue background.

11 **Biofilm formation and detachment assays**

12 Biofilms were formed in 96 well polystyrene plates according to the method of Caiazza
13 and O'Toole (4). Cells were inoculated at a concentration of 10^7 cells/mL into 100 μL 66% TSB
14 containing 0.2% glucose or a mixture of 2% xylose and 2% glucose and incubated for 16 hours at
15 37°C. The culture supernatant and non-adherent bacteria were removed by decanting and then
16 washing the wells three times with water. Biofilms were stained with 0.1% crystal violet for 15
17 minutes, and washed again 3 times with water. The crystal violet was released from the adherent
18 cells with absolute ethanol and quantified by reading its absorbance at 562nm.

19 For detachment studies, pre-formed biofilms were treated with 100 μL 20mM Tris-Cl
20 (pH 7.5), 100 $\mu\text{g}/\text{mL}$ protease K, or 0.14 U/mL DNase I (Roche) at 37°C for 2 hours. Washing
21 and staining of the biofilms were carried out as described above. Data shown are representative

1 of 3 independent experiments with at least 6 replicates each. Error bars represent the standard
2 deviation of the mean. Statistical significance was calculated using the Student's t-test.

3 **RESULTS**

4 **Transcriptional profile of the *sarZ* gene**

5 SarZ was originally identified based on its homology with members of the SarA protein
6 family of *S. aureus*. The *sarZ* locus, SA2174, is located near genes involved in the nitrate/nitrite
7 utilization pathways in *S. aureus*. However, despite this proximity, *sarZ* does not appear to be in
8 an operon with any of them. Directly downstream of *sarZ* is an uncharacterized gene that is
9 predicted to encode a chaperone based on its sequence similarity to genes of the heat shock
10 protein family bearing an alpha-crystallin domain (10).

11 We initially chose to study *sarZ* in the RN6390 background because this strain has been
12 well characterized and is accompanied with an assortment of regulatory mutants which have
13 been evaluated previously (7). However, recognizing that RN6390 has a defective *rsbU*, which
14 is required to activate the alternative sigma factor B, we conducted relevant phenotypic studies in
15 strain SH1000, which has a restored *rsbU* (16, and see below).

16 The transcriptional profile of the *sarZ* gene in the wild-type strain RN6390 during
17 various points of the *S. aureus* cell cycle was assessed by Northern blots (Figure 1B). The *sarZ*
18 transcript appeared as two hybridizing bands, with a predominant species at 450 bp, the expected
19 size of the monocistronic *sarZ* transcript, and a larger species at 1.5 kb, which likely corresponds
20 to the co-transcription of *sarZ* with the putative chaperone SA2175 (Figure 1A). As the growth

1 cycle progressed, the level of *sarZ* transcript reached a maximal level during the late exponential
2 phase (OD₆₅₀ = 1.1). The level of the smaller *sarZ* transcript decreased during the post-
3 exponential phase (OD₆₅₀ = 1.7), while the larger 1.5 kb transcript was not detectable. As
4 expected, both transcripts were undetectable in the *sarZ* mutant, and the temporal pattern of *sarZ*
5 transcription was restored upon complementation of the *sarZ* mutation.

6 **Effect of a *sarZ* mutation on the transcription of regulatory genes**

7 Based on its similarity to SarA, we hypothesized that SarZ may be involved in regulation
8 of the *S. aureus* virulence cascade. To test this hypothesis, the transcriptional profile of a *sarZ*
9 deletion mutant was compared to that of the parental strain RN6390 and a complemented *sarZ*
10 mutant strain. The levels of SarA in two independently isolated *sarZ* mutants were first assessed
11 by immunoblots. Compared to the parent strain, the two *sarZ* mutants had a two- to three-fold
12 increase in SarA protein level, suggesting that SarZ may have had a repressive effect on SarA
13 expression (Figure 2A). To confirm this, we analyzed *sarA* transcription in the *sarZ* mutant.
14 The *sarA* locus is composed of three overlapping transcripts initiating from three distinct
15 promoters, P1, P2, and P3 (21) that all encompass the *sarA* coding region. Northern blot data
16 revealed that the *sarZ* mutant demonstrated a moderate increase in the *sarA* P1 transcript during
17 late exponential phase (OD₆₅₀ = 1.1) as compared with the parental and complemented strains
18 (Fig 2B left panel). The level of the *sarA* P1 transcript in the mutant was similar to that of the
19 parent during the post-exponential phase. GFP-promoter fusion analysis, which reflects the
20 cumulative promoter activity, indicated that the three strains had equivalent levels of P1
21 promoter activity during growth. When the collective strength of the native triple *sarA* promoter

1 was investigated, its activity in the *sarZ* mutant was moderately, but significantly ($p = 0.001$)
2 increased in comparison with the wild-type and complemented strains (Figure 2B, right panel).

3 As SarA is a key regulator of *agr*, the level of *agr* RNAIII transcription was assessed in
4 the *sarZ* mutant (Figure 2C). Both Northern blot and GFP-promoter fusion analysis indicated
5 that the RNAIII transcript, the *agr* effector molecule, was strongly down-regulated in the *sarZ*
6 mutant in comparison with the wild-type and complemented strains.

7 Given that the levels of SarA were increased in a *sarZ* deficient background and that
8 SarA is an activator of *agr*, we reasoned that SarZ may have exerted its effect on *agr*
9 independently of SarA. To evaluate this, we investigated the possibility that SarZ may have
10 acted upon downstream genes via SarR, a repressor of SarA and activator of *agr* (22). However,
11 the level of *sarR* transcription was unchanged in the *sarZ* mutant in comparison to the wild-type
12 (data not shown), implying that SarZ likely activated *agr* independently of SarR as well as SarA.

13 **Effect of a *sarZ* mutation on the transcription of virulence genes**

14 The repression of SarA and activation of *agr* by SarZ suggested that SarZ was an
15 important player in the *S. aureus* virulence cascade. Therefore, the transcription of three
16 virulence factor genes, controlled differentially by both SarA and *agr*, was examined in an
17 attempt to delineate the regulatory network controlled by SarZ. The expression of the protein A
18 gene, *spa*, is repressed by both SarA and *agr*. Northern blot analysis indicated that *spa*
19 transcription was increased two-fold in the *sarZ* mutant in comparison with the wild-type and
20 complemented strains (Figure 3A, left panel). This up-regulation was confirmed by GFP-
21 promoter fusion analysis. Given that SarA levels were increased in the *sarZ* mutant while

1 RNAIII levels were decreased, these data indicated that SarZ probably represses *spa* expression
2 by acting through a pathway mediated by *agr*. Indeed, provision of RNAIII *in trans* to the *sarZ*
3 mutant halved the transcription of *spa*. As expected, removing *sarA*, a strong repressor of *spa*,
4 from the *sarZ* mutant, increased *spa* transcription by approximately 2.4 fold (Figure 3A centre
5 panel) indicating that these two regulators exert their effects upon *spa* independently of each
6 other.

7 The transcription of *hla*, which encodes alpha hemolysin, was moderately reduced in
8 post-exponentially growing *sarZ* mutant cells in comparison to the wild-type and complemented
9 strains (0.7 vs. 1, Figure 3B). The decrease in *hla* promoter activity was more evident by
10 analyzing the GFP-promoter fusion activities during the growth cycle in the mutant versus the
11 parent and complemented mutant strains. Deleting *sarA* from the *sarZ* mutant, decreased *hla*
12 transcription by 5 fold while providing RNAIII *in trans* increased *hla* transcription back to wild-
13 type levels. Since *sarZ* activated *agr* while repressing *sarA*, and both of these activate *hla*, these
14 data implied that the net effect of SarZ on *hla* transcription may be due to competing forces of
15 *agr* and SarA.

16 The gene encoding the serine protease, *sspA*, is differentially regulated by *agr* and SarA.
17 SarA represses the protease gene while *agr* activates it. As predicted, from the effect of *sarZ*
18 upon SarA and *agr*, the transcription of *sspA* was markedly reduced (by approximately 10-fold)
19 on deletion of the *sarZ* gene (Figure 3C, left panel). However, when *sarA* was deleted from the
20 *sarZ* mutant or when RNAIII was provided *in trans*, the level of *sspA* transcription did not
21 increase as expected (Figure 3C, centre panel). These, data indicate that *sarZ* may activate *sspA*

1 independently of both SarA and *agr*. Consistent with the transcriptional data, the *sarZ* mutant
2 did not exhibit any detectable protease activity on either a skimmed milk agar plate or
3 polyacrylamide gel containing gelatin (Figure 3D).

4 **Involvement of SarZ in biofilm formation**

5 During the course of this work, it was noted that liquid cultures of the *sarZ* mutant settled
6 out of solution more readily than either the wild-type or complemented strains, a phenotype that
7 is frequently seen in biofilm producing strains. Accordingly, a biofilm formation assay in a 96-
8 well polystyrene plate format was performed; the *sarZ* mutant was found to have an increased
9 ability to form biofilms in comparison to the parent and complemented mutant (Figure 4A).

10 In *S. aureus*, the major biofilm exopolysaccharide, poly-N-acetylglucosamine (PNAG), is
11 encoded by the *icaADBC* operon (12). However, Northern blot and GFP-promoter fusion
12 analyses failed to demonstrate an alteration in the transcription of the *ica* genes in a *sarZ* mutant
13 (data not shown) suggesting that the major constituent of biofilms formed by the *sarZ* mutant
14 was not PNAG. Treatment of preformed biofilms with proteinase K promoted detachment of the
15 biofilms, whereas treatment with DNase I did not. This result suggested that the biofilm forming
16 capacity of the *sarZ* mutant was likely protein-mediated (Figure 4B).

17 We also reasoned that the ability of the *sarZ* mutant to produce robust biofilms may have
18 been due to the marked reduction in endogenous protease production. To confirm this
19 hypothesis, the *sspA* gene was provided *in trans* to the mutant. The resultant strain was able to
20 produce protease (Figure 5, middle panel) and more importantly, exhibited reduced biofilm
21 formation, to the level of the parental strain (Figure 5, top and bottom panels).

1 **Effect of SarZ on MgrA expression**

2 Recently, unpublished data from our lab has demonstrated that another SarA homologue,
3 MgrA, was involved in the repression of biofilm formation in an *ica*-independent manner, akin to
4 that of SarZ. Hence, we sought to determine whether SarZ was involved in the regulation of
5 MgrA. Both Northern and GFP-promoter fusion analyses demonstrated a noticeable decrease in
6 *mgrA* transcriptional activity in the *sarZ* mutant as compared with the parent, consistent with the
7 notion that SarZ is an activator of *mgrA* (Figure 6A). Provision of *mgrA in trans* under the
8 control of an exogenous promoter was able to curtail biofilm formation of the *sarZ* mutant down
9 to the levels of the wild-type strain (Figure 6B). Although *sarZ* and *mgrA* are both positive
10 regulators of *agr* and *sspA*, the effect of SarZ on biofilms likely occurred independently of *agr*
11 and *sspA* since provision of *mgrA* to the *sarZ* mutant *in trans* did not complement the
12 transcription of these two genes nor did it restore protease production in the *sarZ* mutant (Figure
13 6C).

14 **Role of SarZ in *S. aureus* strain SH1000**

15 Our current understanding of virulence gene regulation in *S. aureus* is due primarily
16 through the study of laboratory strains derived from or closely related to RN6390 (16, 22, 26,
17 36). RN6390, however, has a deletion in *rsbU*, which encodes a phosphatase required for the
18 activation of the alternative sigma factor B. As SigB has been implicated in the control of
19 several virulence genes and biofilm formation, we sought to determine whether the effects we
20 observed in the *sarZ* mutant of RN6390 were applicable to strain SH1000, a strain similar to
21 RN6390 but with a restored *rsbU* (15). As observed with strain RN6390, *sarZ* was transcribed

1 maximally in SH1000 during the late exponential phase of growth (Figure 7A). Analysis of the
2 levels of SarA, *agr*, and *mgrA* in two independently isolated *sarZ* mutants in SH1000 also
3 mirrored results obtained from strain RN6390. In particular, the SarA protein level appeared to
4 be repressed by SarZ, while transcription of *agr* and *mgrA* was activated by *sarZ* (Figure 7B). In
5 association with these regulatory changes, the *sarZ* mutant of SH1000 also demonstrated
6 enhanced biofilm production as compared with the parent (Figure 7C). These data suggest that
7 the regulatory profile and the biofilm positive phenotype of the *sarZ* mutants occurred
8 independently of the alternative sigma factor B.

9 DISCUSSION

10 In this study, we have shown by transcriptional and phenotypic analyses that SarZ plays
11 an important role in the *S. aureus* virulence cascade (Figure 8). Inactivation of *sarZ* in two
12 strains of *S. aureus* resulted in elevated production of SarA in comparison to the respective
13 parental strains. Using strain RN6390 as a model and building upon the accumulated regulatory
14 data on this strain, we found that a mutation in *sarZ* decreased *agr* transcription. Consistent with
15 an *agr* deficient phenotype, the transcription of *spa* was increased in the *sarZ* mutant, while the
16 transcription of *hla* was decreased. Given that SarA up-regulates *hla* and down-modulates *spa*, it
17 is likely that the effect of SarZ on protein A and alpha-hemolysin gene expression was mediated
18 primarily via *agr* rather than SarA (27). The drastic reduction of *sspA* transcription was first
19 thought to be due to the augmented SarA expression and/or decreased *agr* RNAIII levels in the
20 *sarZ* mutant. However, subsequent results with a *sarA sarZ* double mutant and a *sarZ* mutant
21 over expressing RNAIII demonstrated that the effect of *sarZ* upon *sspA* likely occurred

1 independently of these two global regulators. Previous work by Kaito *et al.* (18) demonstrated
2 the direct binding of SarZ to the *hla* and *agr* promoter, thus providing evidence that SarZ may
3 directly regulate these genes. Whether this DNA binding activity also applies to the *sarA*, *sspA*,
4 or *spa* promoters will require further study, especially in light of the finding that the binding of
5 SarZ to DNA may be non-specific (18).

6 Our observation that *sarZ* represses *sarA* (an activator of *agr*) and up-regulates *agr*
7 suggested that the activation of *agr* by SarZ occurred independently of SarA. We initially
8 hypothesized that SarZ may have acted via SarR, a repressor of SarA and activator of *agr* (22).
9 However, analysis of *sarR* transcription in a *sarZ* mutant did not reveal any reproducible changes
10 with respect to the wild-type strain, suggesting that SarZ likely regulates *agr* and *sarA*
11 independently of SarR. Based on the observed decrease in *mgrA* transcription in the *sarZ* mutant
12 and its role in *agr* activation (16), MgrA was next examined as a potential intermediary between
13 SarZ and *agr*. Provision of MgrA under the control of an exogenous promoter to the *sarZ*
14 mutant repressed biofilm formation but was not sufficient in restoring the transcription of *agr*
15 and its downstream target genes, *sspA* and *hla* (Figure 6 - *hla* data not shown), suggesting that
16 SarZ or another factor controlled by SarZ was required for optimal *agr* activation. Detailed
17 analysis of the binding activity of SarZ to the RNAlII promoter, alone and/or in conjunction with
18 other regulators such as SarA and MgrA are required to fully appreciate the mechanistic details
19 of *agr* regulation by SarZ.

20 The effect of *sarZ* on *sarA* expression is quite complex due to the intricacy of the triple
21 promoters that drive the expression of *sarA* (5). Northern blot analysis revealed that *sarZ* may

1 repress *sarA* due to its effect on the proximal P1 promoter during late exponential phase, which
2 coincides with maximal *sarZ* transcription. GFP-promoter fusion analysis, however, suggested
3 that the effect of SarZ upon *sarA* transcription may have been attributed to the cumulative
4 actions of SarZ on all three promoters throughout the growth cycle rather than on the *sarA* P1
5 promoter alone. Whether the discrepancy between *sarA* promoter activity and SarA protein
6 expression levels in the *sarZ* mutant are attributable to an additional level of post-transcriptional
7 control or in conjunction with other regulator(s) remains to be defined. Indeed, both SarA and
8 SarR can bind to and repress the *sarA* P1 promoter, thus indicating the complexity through which
9 SarA protein expression may be controlled in *S. aureus* (6, 20).

10 As the *sarZ* mutant exhibited elevated SarA protein expression, we speculated that the
11 *sarZ* mutant may have an enhanced biofilm phenotype. Previously, SarA has been shown to be
12 essential to biofilm formation by activating the *ica* genes which are required to synthesize
13 PNAG, a major biofilm matrix component, and *bap* encoding a protein adhesin found only in
14 bovine isolates of *S. aureus* (33). However, the transcription of the *ica* genes was not altered in
15 the *sarZ* mutant as compared with the parental strain. Detachment studies with Proteinase K and
16 DNase I indicated that the major constituents of biofilms of *sarZ* mutants are likely proteins
17 rather than a carbohydrate such as PNAG. Accordingly, there appeared to be two plausible
18 scenarios by which SarZ may repress biofilm formation in *S. aureus*: (a) by repressing surface
19 adhesin expression via down-regulation of SarA and/or (b) through the activation of an
20 inhibitory or detachment factor such as a protease. One likely candidate for a detachment factor
21 was the V8 protease, SspA, since it was strongly repressed in the *sarZ* mutant. Provision of *sspA*
22 *in trans* to the mutant restored the biofilm phenotype to the parental level. However, a recent

1 publication as well as unpublished data from our lab have demonstrated that an *sspA* mutant
2 alone does not result in an enhanced biofilm phenotype, contrary to what one would expect if
3 SspA was a major detachment factor (2). Therefore, we conclude that while *sspA* is not essential
4 for biofilm formation, high levels of the protease can contribute to biofilm detachment by acting
5 as a general protease, much like Proteinase K.

6 MgrA has also been described as a negative regulator of biofilm formation that acts in an
7 *ica* independent manner (34). Given the similarities between the biofilms of *sarZ* and *mgrA*
8 mutants, we sought to determine whether SarZ controlled *mgrA* with respect to biofilm
9 formation. Indeed, *mgrA* transcription was decreased in the *sarZ* mutant in comparison to the
10 wild-type strain. Importantly, the enhanced biofilm phenotype of the *sarZ* mutant returned to
11 near parental levels when *mgrA* was provided *in trans* via a plasmid with a xylose-inducible
12 promoter. We also monitored *agr* and *sspA* transcription in this *sarZ* mutant derivative and
13 determined that this MgrA over-producing construct did not restore the transcription of these
14 genes to the levels of the parental strain, RN6390. The lack of protease activity in this *sarZ*
15 mutant derivative implied that increased expression of surface adhesin(s), possibly via the down
16 regulation of *mgrA* and/or *agr* may account for the enhanced biofilm phenotype in the absence of
17 SarZ. Whether the upregulation of SarA in the *sarZ* mutant contributes to further enhancement
18 of biofilm formation via the expression of additional surface protein adhesion(s) remains to be
19 determined.

20 Taken together, our results demonstrate that SarZ up-regulates *agr* and represses SarA
21 expression to promote the expression of virulence genes such as *hla* and *sspA*. Additionally, the

1 *sarZ* locus also controls *mgrA* and *agr* to repress biofilm formation. Repressing biofilm
2 formation prevents the establishment of sessile bacterial communities, and hence promotes active
3 infections. In addition, concomitant expression of toxic proteins such as alpha-hemolysin and
4 V8 protease in a *sarZ* positive strain, would lead to tissue damage and promote the spread of
5 bacteria to new infection sites. Accordingly, we propose that SarZ is an important regulator
6 required for the maintenance and spread of active *S. aureus* infections.

7 ACKNOWLEDGEMENTS

8 This work was supported in part by NIH grant AI37142 to ALC. We thank Niles
9 Donegan for critical reading of the manuscript.

10 REFERENCES

- 11 1. **Arnaud, M., A. Chastanet, and M. Debarbouille.** 2004. New vector for efficient allelic
12 replacement in naturally nontransformable, low-GC-content, gram-positive bacteria. Appl
13 Environ Microbiol **70**:6887-91.
- 14 2. **Boles, B. R., and A. R. Horswill.** 2008. Agr-mediated dispersal of *Staphylococcus*
15 *aureus* biofilms. PLoS Pathog **4**:e1000052.
- 16 3. **Bronner, S., H. Monteil, and G. Prevost.** 2004. Regulation of virulence determinants in
17 *Staphylococcus aureus*: Complexity and applications. FEMS Microbiol Rev **28**:183-200.
- 18 4. **Caiazza, N. C., and G. A. O'Toole.** 2003. Alpha-toxin is required for biofilm formation
19 by *Staphylococcus aureus*. J Bacteriol **185**:3214-7.
- 20 5. **Cheung, A. L., and A. C. Manna.** 2005. Role of the distal *sarA* promoters in SarA
21 expression in *Staphylococcus aureus*. Infect Immun **73**:4391-4.
- 22 6. **Cheung, A. L., K. Nishina, and A. C. Manna.** 2008. SarA of *Staphylococcus aureus*
23 binds to the *sarA* promoter to regulate gene expression. J Bacteriol **190**:2239-43.
- 24 7. **Cheung, A. L., K. A. Nishina, M. P. Trotonda, and S. Tamber.** 2008. The SarA
25 protein family of *Staphylococcus aureus*. Int J Biochem Cell Biol **40**:355-61.
- 26 8. **Cheung, A. L., S. J. Projan, and H. Gresham.** 2002. The Genomic Aspect of
27 Virulence, Sepsis, and Resistance to Killing Mechanisms in *Staphylococcus aureus*. Curr
28 Infect Dis Rep **4**:400-410.
- 29 9. **Chien, Y., A. C. Manna, S. J. Projan, and A. L. Cheung.** 1999. SarA, a global
30 regulator of virulence determinants in *Staphylococcus aureus*, binds to a conserved motif
31 essential for *sar*-dependent gene regulation. J Biol Chem **274**:37169-76.

- 1 10. **de Jong, W. W., J. A. Leunissen, and C. E. Voorter.** 1993. Evolution of the alpha-
2 crystallin/small heat-shock protein family. *Mol Biol Evol* **10**:103-26.
- 3 11. **Dunman, P. M., E. Murphy, S. Haney, D. Palacios, G. Tucker-Kellogg, S. Wu, E. L.**
4 **Brown, R. J. Zagursky, D. Shlaes, and S. J. Projan.** 2001. Transcription profiling-
5 based identification of *Staphylococcus aureus* genes regulated by the *agr* and/or *sarA*
6 loci. *J Bacteriol* **183**:7341-53.
- 7 12. **Fitzpatrick, F., H. Humphreys, and J. P. O'Gara.** 2005. The genetics of
8 staphylococcal biofilm formation--will a greater understanding of pathogenesis lead to
9 better management of device-related infection? *Clin Microbiol Infect* **11**:967-73.
- 10 13. **Forsyth, R. A., R. J. Haselbeck, K. L. Ohlsen, R. T. Yamamoto, H. Xu, J. D.**
11 **Trawick, D. Wall, L. Wang, V. Brown-Driver, J. M. Froelich, K. G. C, P. King, M.**
12 **McCarthy, C. Malone, B. Misiner, D. Robbins, Z. Tan, Z. Y. Zhu Zy, G. Carr, D. A.**
13 **Mosca, C. Zamudio, J. G. Foulkes, and J. W. Zyskind.** 2002. A genome-wide strategy
14 for the identification of essential genes in *Staphylococcus aureus*. *Mol Microbiol*
15 **43**:1387-400.
- 16 14. **Geisinger, E., R. P. Adhikari, R. Jin, H. F. Ross, and R. P. Novick.** 2006. Inhibition of
17 rot translation by RNAIII, a key feature of *agr* function. *Mol Microbiol* **61**:1038-48.
- 18 15. **Horsburgh, M. J., J. L. Aish, I. J. White, L. Shaw, J. K. Lithgow, and S. J. Foster.**
19 2002. *sigmaB* modulates virulence determinant expression and stress resistance:
20 Characterization of a functional *rsbU* strain derived from *Staphylococcus aureus* 8325-4.
21 *J Bacteriol* **184**:5457-67.
- 22 16. **Ingavale, S., W. van Wamel, T. T. Luong, C. Y. Lee, and A. L. Cheung.** 2005.
23 Rat/MgrA, a regulator of autolysis, is a regulator of virulence genes in *Staphylococcus*
24 *aureus*. *Infect Immun* **73**:1423-31.
- 25 17. **Kahl, B. C., M. Goulian, W. van Wamel, M. Herrmann, S. M. Simon, G. Kaplan, G.**
26 **Peters, and A. L. Cheung.** 2000. *Staphylococcus aureus* RN6390 replicates and induces
27 apoptosis in a pulmonary epithelial cell line. *Infect Immun* **68**:5385-92.
- 28 18. **Kaito, C., D. Morishita, Y. Matsumoto, K. Kurokawa, and K. Sekimizu.** 2006. Novel
29 DNA binding protein SarZ contributes to virulence in *Staphylococcus aureus*. *Mol*
30 *Microbiol* **62**:1601-17.
- 31 19. **Kupferwasser, L. I., M. R. Yeaman, C. C. Nast, D. Kupferwasser, Y. Q. Xiong, M.**
32 **Palma, A. L. Cheung, and A. S. Bayer.** 2003. Salicylic acid attenuates virulence in
33 endovascular infections by targeting global regulatory pathways in *Staphylococcus*
34 *aureus*. *J Clin Invest* **112**:222-33.
- 35 20. **Manna, A., and A. L. Cheung.** 2001. Characterization of *sarR*, a modulator of *sar*
36 expression in *Staphylococcus aureus*. *Infect Immun* **69**:885-96.
- 37 21. **Manna, A. C., M. G. Bayer, and A. L. Cheung.** 1998. Transcriptional analysis of
38 different promoters in the *sar* locus in *Staphylococcus aureus*. *J Bacteriol* **180**:3828-36.
- 39 22. **Manna, A. C., and A. L. Cheung.** 2006. Transcriptional regulation of the *agr* locus and
40 the identification of DNA binding residues of the global regulatory protein SarR in
41 *Staphylococcus aureus*. *Mol Microbiol* **60**:1289-301.
- 42 23. **Novick, R. P.** 2003. Autoinduction and signal transduction in the regulation of
43 staphylococcal virulence. *Mol Microbiol* **48**:1429-49.

- 1 24. **Novick, R. P.** 1990. The *Staphylococcus* as a molecular genetic system. . VCH
2 Publishers, New York, NY.
- 3 25. **Novick, R. P., and D. Jiang.** 2003. The staphylococcal *saeRS* system coordinates
4 environmental signals with *agr* quorum sensing. *Microbiology* **149**:2709-17.
- 5 26. **Oscarsson, J., C. Harlos, and S. Arvidson.** 2005. Regulatory role of proteins binding to
6 the *spa* (protein A) and *sarS* (staphylococcal accessory regulator) promoter regions in
7 *Staphylococcus aureus* NTCC 8325-4. *Int J Med Microbiol* **295**:253-66.
- 8 27. **Oscarsson, J., A. Kanth, K. Tegmark-Wisell, and S. Arvidson.** 2006. SarA is a
9 repressor of *hla* (alpha-hemolysin) transcription in *Staphylococcus aureus*: its apparent
10 role as an activator of *hla* in the prototype strain NCTC 8325 depends on reduced
11 expression of *sarS*. *J Bacteriol* **188**:8526-33.
- 12 28. **Oscarsson, J., K. Tegmark-Wisell, and S. Arvidson.** 2006. Coordinated and
13 differential control of aureolysin (*aur*) and serine protease (*sspA*) transcription in
14 *Staphylococcus aureus* by *sarA*, *rot* and *agr* (RNAIII). *Int J Med Microbiol* **296**:365-80.
- 15 29. **Projan, S. J., and R. P. Novick.** 1997. The molecular basis of pathogenicity. W.B.
16 Saunders Company, Philadelphia, PA.
- 17 30. **Rasband, W. S.** 1997-2007. ImageJ. U. S. National Institutes of Health, Bethesda, MD.
- 18 31. **Schenk, S., and R. A. Laddaga.** 1992. Improved method for electroporation of
19 *Staphylococcus aureus*. *FEMS Microbiol Lett* **73**:133-8.
- 20 32. **Schmidt, K. A., A. C. Manna, S. Gill, and A. L. Cheung.** 2001. SarT, a repressor of
21 alpha-hemolysin in *Staphylococcus aureus*. *Infect Immun* **69**:4749-58.
- 22 33. **Trotonda, M. P., A. C. Manna, A. L. Cheung, I. Lasa, and J. R. Penades.** 2005. SarA
23 positively controls *bap*-dependent biofilm formation in *Staphylococcus aureus*. *J*
24 *Bacteriol* **187**:5790-8.
- 25 34. **Trotonda, M. P., S. Tamber, G. Memmi, and A. L. Cheung.** 2008. MgrA represses
26 biofilm formation in *Staphylococcus aureus*. *Infect Immun*. In Press.
- 27 35. **Vandenesch, F., J. Kornblum, and R. P. Novick.** 1991. A temporal signal, independent
28 of *agr*, is required for *hla* but not *spa* transcription in *Staphylococcus aureus*. *J Bacteriol*
29 **173**:6313-20.
- 30 36. **Xiong, Y. Q., J. Willard, M. R. Yeaman, A. L. Cheung, and A. S. Bayer.** 2006.
31 Regulation of *Staphylococcus aureus* alpha-toxin gene (*hla*) expression by *agr*, *sarA*, and
32 *sae* *in vitro* and in experimental infective endocarditis. *J Infect Dis* **194**:1267-75.
- 33

1
2

TABLES

Table 1. Bacterial strains and plasmids used in this study

<i>S. aureus</i>	Description	Reference
RN4220	Heavily mutagenized strain that accepts foreign DNA, <i>agr</i> -	(24)
RN6390	Laboratory strain related to strain 8325-4	(29)
SH1000	8325-4 with <i>rsbU</i> restored	(15)
ALC6374	RN6390 Δ <i>sarZ</i>	This work
ALC6366	SH1000 Δ <i>sarZ</i>	This work
ALC6367	RN6390 Δ <i>sarZ</i> / <i>sarZ</i> complement	This work
ALC6368	RN6390 Δ <i>sarZ</i> with pEPSA5	This work
ALC6369	RN6390 Δ <i>sarZ</i> with pEPSA5:: <i>sspA</i>	This work
ALC6370	RN6390 Δ <i>sarZ</i> with pEPSA5:: <i>mgrA</i>	This work
ALC6410	RN6390 Δ <i>sarZ</i> Δ <i>sarA</i>	This work
ALC6409	RN6390 Δ <i>sarZ</i> with pRN6735 (<i>blaZ</i> promoter driving RNAIII)	This work
<i>E. coli</i>		
TOP10	General cloning strain	
Plasmids		
pMAD	<i>E. coli</i> - <i>S. aureus</i> shuttle vector containing a thermosensitive origin of replication <i>bgaB</i> , <i>em</i> ^R , <i>ap</i> ^R	(1)
pEPSA5	<i>E. coli</i> - <i>S. aureus</i> shuttle vector containing a xylose inducible promoter, <i>ap</i> ^R , <i>cm</i> ^R	(13)
pALC1484	<i>E. coli</i> - <i>S. aureus</i> shuttle vector derivatized from pSK236 containing the <i>gfp</i> _{uvr} gene, <i>ap</i> ^R , <i>cm</i> ^R	(17)
pALC1540	<i>sarA</i> triple promoter driving the expression of <i>gfp</i> _{uvr} in pALC1484	(21)
pALC1435	<i>sarA</i> P1 promoter driving the expression of <i>gfp</i> _{uvr} in pALC1484	(21)

pALC1743	<i>agr</i> P3 promoter driving the expression of <i>gfp_{uvr}</i> in pALC1484	(17)
pALC1741	<i>spa</i> promoter driving the expression of <i>gfp_{uvr}</i> in pALC1484	(19)
pALC1740	<i>hla</i> promoter driving the expression of <i>gfp_{uvr}</i> in pALC1484	(19)
pALC2831	<i>sspA</i> promoter driving the expression of <i>gfp_{uvr}</i> in pALC1484	This work
pALC2566	<i>mgrA</i> promoter driving the expression of <i>gfp_{uvr}</i> in pALC1484	This work
pALC5448	pMAD containing a <i>sarA</i> deletion fragment generated by PCR	(34)
pRN6735	<i>blaZ</i> promoter driving the expression of promoterless RNAIII, <i>cm^R</i>	(35)

ACCEPTED

1 **FIGURE LEGENDS**

2 **Figure 1. Transcription of *sarZ* during the exponential and post-exponential phases of**
3 **growth. A.** Genomic context of the *sarZ* gene. Numbers within the block arrows indicate the
4 lengths of the genes in base pairs, numbers above the arrows indicate the length of the intergenic
5 regions in also in base pairs. **B.** Left panel. Northern blot analysis of *sarZ* transcription in
6 RN6390 during the early ($OD_{650} = 0.7$), late ($OD_{650} = 1.1$), and post ($OD_{650} = 1.7$) exponential
7 phases of growth. Right panel. Northern blot analysis of *sarZ* transcription in the wild-type
8 RN6390, *sarZ* mutant and complemented *sarZ* mutant strains of *S. aureus* during late-
9 exponential and post-exponential growth. Panels below the Northern blots show the 23S and
10 16S which served as the internal loading control.

11 **Figure 2. Effect of *sarZ* on the expression of *sarA* and *agr*.** **A.** Western blot analysis of SarA
12 protein expression in the wild-type RN6390 and two independently isolated *sarZ* mutant clones
13 of *S. aureus*. **B and C.** Left panels. Northern blot analysis of *sarA* (B) and *agr* RNA III (C)
14 transcription in the wild-type RN6390, *sarZ* mutant, and complemented *sarZ* mutant strains of *S.*
15 *aureus*. Right panels. GFP-fusion analysis of the *sarA* triple promoter (black), *sarA* P1
16 promoter (grey), and *agr* RNAIII promoter activity in RN6390, *sarZ* mutant, and complemented
17 strains of *S. aureus*. Numbers underneath the panels indicate the relative intensities or sum of
18 the intensities of the bands as determined by Image J. Panels below the Northern blots show the
19 23S and 16S rRNA which served as the internal loading control. * $p < 0.01$ as determined by the
20 Student's t-test.

1 **Figure 3. Effect of *sarZ* on the transcription of *spa*, *hla* and *sspA*.** Left and centre panels.
2 Northern blot analyses of *spa* (A.), *hla* (B.), and *sspA* (C.) in the RN6390 wild-type, *sarZ*
3 mutant, complemented *sarZ* mutant strains (left panel); *sarZ* mutant, RN6390, *sarZ* mutant
4 expressing RNAIII *in trans* and *sarZ sarA* double mutant (centre panel). RNA was harvested
5 from late-exponentially (*spa*) or post-exponentially (*hla*, *sspA*) growing *S. aureus*. The lightness
6 of the *spa* band in the middle panel of Fig. 3A was due to underexposure of the film to allow us
7 to visualize the intensity of the *spa* band in the *sarZ sarA* double mutant. Numbers underneath
8 the panels indicate the relative intensities of the bands as determined by Image J. Right panels.
9 GFP-fusion analyses of the *spa* (A.), *hla* (B.), and *sspA* (C.) promoter activities in RN6390, *sarZ*
10 mutant, and complemented strains of *S. aureus*. * $p < 0.01$ as determined by the Student's t-test.
11 **D.** Protease activity of the wild-type RN6390, *sarZ* mutant, and complemented *sarZ* mutant
12 strains of *S. aureus*. Top panel; proteolysis on skimmed milk agar. Lower panel; proteolysis on
13 a gelatin-containing polyacrylamide gel.

14 **Figure 4. A *sarZ* mutant hyperproduces biofilms rich in proteins.** A. Quantitation of
15 biofilm formation on 96-well polystyrene plates. * $p < 0.01$ compared to the wild-type strain
16 RN6390 as determined by the Student's t-test. B. Detachment of biofilms formed by RN6390
17 (black) and the *sarZ* mutant (white) after treatment with Proteinase K or DNase I for 2 hours. *
18 $p < 0.01$ compared to the buffer control. ** $p > 0.05$ compared to the buffer control. Panels
19 beneath the graphs show representative wells with the crystal violet staining phenotype of the
20 biofilms.

1 **Figure 5. Protease mediated detachment of biofilms produced by a *sarZ* mutant.** Top,
2 biofilm formation of RN6390, the *sarZ* mutant, and the *sarZ* mutants containing either pEPSA5
3 (VC), or pEPSA5::*sspA* (SspA). Cells were grown on 66% TSB, 2% glucose and 2% xylose to
4 induce both biofilm formation and SspA production. * $p < 0.01$ compared to the parental strain
5 RN6390 as determined by the Student's t-test. ** $p > 0.05$ compared to the RN6390 parental
6 strain. Middle panels, protease activity of the indicated strains on a gelatin-containing
7 polyacrylamide gel. Bottom panels, representative wells showing the crystal violet staining
8 phenotype of the biofilms.


9 **Figure 6. Effect of *sarZ* on *mgrA*.** **A.** Left panel. Northern blot analysis of *mgrA* transcription
10 in RN6390, *sarZ* mutant, and complemented *sarZ* mutant strains of *S. aureus* during late
11 exponential phase. Numbers underneath the panels indicate the relative intensities of the bands
12 as determined by Image J. Right panel. GFP-fusion analysis of the *mgrA* promoter activity in
13 RN6390, *sarZ* mutant, and complemented strains of *S. aureus*. * $p < 0.01$ as determined by the
14 Student's t-test. **B.** Top, biofilm formation of RN6390, the *sarZ* mutant, and the *sarZ* mutants
15 containing pEPSA5 (VC) or pEPSA5::*mgrA* (MgrA). Cells were grown on 66% TSB, 2%
16 glucose and 2% xylose to induce both biofilm formation and MgrA production. * $p < 0.01$
17 compared to RN6390 ** $p > 0.05$ compared to RN6390. Bottom panels, representative wells
18 showing the crystal violet staining phenotype of the biofilms. **C.** Top two panels, transcription
19 of *agr* and *sspA* in RN6390, *sarZ* mutant, and complemented *sarZ* mutant strains of *S. aureus*. as
20 determined by Northern blot. Numbers beside the panels indicate the relative intensities of the
21 bands as determined by Image J. Bottom panels, protease activity of the indicated strains on a
22 gelatin-containing polyacrylamide gel.

1 **Figure 7. Effects of *sarZ* are conserved in SH1000.** **A.** Transcription of *sarZ* during the early
2 (OD₆₅₀ = 0.7), late (OD₆₅₀ = 1.1), and post (OD₆₅₀ = 1.7) exponential phases of growth. **B.**
3 Effect of *sarZ* upon *SarA*, *agr*, and *mgrA* expression during late (*SarA*, *mgrA*) and post-
4 exponential (*agr*) growth. Top panel, protein levels of *SarA* in the SH1000 wild-type strain and
5 two independently isolated *sarZ* mutant clones of *S. aureus* as determined by Western blot
6 analysis. Middle and bottom panels, Northern blot analysis of the transcription of *agr* RNAIII
7 (middle) and *mgrA* (bottom) in the wild-type SH1000 strain and two independently isolated *sarZ*
8 mutant clones of *S. aureus*. Numbers beneath the panels indicate the relative intensities of the
9 bands as determined by Image J. **C.** Biofilm formation of SH1000 and an isogenic *sarZ* mutant
10 in a 96 well polystyrene plate. * $p < 0.05$ as determined by the Student's t-test.

11 **Figure 8. Proposed mechanism of virulence gene regulation by SarZ.** SarZ represses *sarA*
12 and activates *mgrA*, leading to the down regulation of genes important to biofilm formation.
13 Activation of *agr* by SarZ also leads to the up-regulation of *hla* (alpha-hemolysin) and repression
14 of *spa* (protein A). Additionally, SarZ activates the production of the SspA protease
15 independently of both *agr* and *sarA*. These changes in gene expression result in a net decrease
16 in surface adhesins and increase in toxins, which likely enable the bacteria to spread to new sites
17 of infection.

Figure 1.

A.



B.




Figure 2.




Figure 3.










Figure 4.




Figure 5.




Figure 6.






Figure 7.






Figure 8.

